Abstract: The present invention provides a human artificial chromosome vector comprising a gene encoding the human antibody heavy chain, a gene encoding the human antibody light chain, and a gene encoding IgM heavy chain constant region derived from a nonhuman animal; and being capable of producing a human antibody with a higher efficiency when the vector is introduced into an animal. By immunizing the animal produced using a human artificial chromosome vector of the present invention with a desired antigen, a large quantity of human polyclonal antibodies can be supplied.
Abstract: A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, an ?-amino acid, an oxidant and water is provided along with temperature conditions to effectively form nanoparticles. These biocompatible nanoparticles may be further conjugated to biologically active agents, such as plasmid DNA, siRNA or proteins, such that a cell transfection agent is formed.
Type:
Grant
Filed:
April 17, 2013
Date of Patent:
April 12, 2016
Assignee:
CERION LLC
Inventors:
Wendi Ann Costanzo, Kenneth Joseph Reed, Bradford Michael Stadler
Abstract: A conditional knock-out non-human animal is disclosed. Wherein some cells of the non-human animal but not all the cells comprise a disrupted MO-1 nucleic acid sequence, wherein the disruption results in an inability of the non-human animal to produce detectable levels of the MO-1 protein, as assayed by Southern blot analysis.
Type:
Grant
Filed:
November 8, 2010
Date of Patent:
March 29, 2016
Assignee:
Medical Research & Development Fund for Health Services Bnai Zion Medical Center, THE STATE OF ISRAEL
Abstract: A tissue handling apparatus is provided comprising a support and a locator, for processing and embedding tissue samples. The support and cover form a chamber, within which a tissue sample is oriented prior to processing. After processing, the tissue sample within the chamber is embedded and the locator is removed, leaving the tissue sample correctly oriented in embedding material, mounted to a support, ready for microtoming.
Type:
Grant
Filed:
September 6, 2006
Date of Patent:
January 12, 2016
Assignee:
LEICA BIOSYSTEMS MELBOURNE PTY LTD
Inventors:
Eduardo Vom, Chester John Henderson, Neville John Farmer
Abstract: This application discloses a light-responsive hydrogel-based platform that can modulate multiple microenvironmental signals to direct the differentiation of human induced pluripotent stem cell-derived neural progenitor cells (hiPSC-NPCs) into neuronal cells. The invention provides novel methods for directing differentiation of neural stem cells into neurons useful for treatment of degenerative diseases or disorders, including but not limited to Alzheimer's, Parkinson's, or spinal cord injury (SCI).
Type:
Grant
Filed:
December 8, 2011
Date of Patent:
January 12, 2016
Assignee:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: An expanding agent for hematopoietic stem cells and/or hematopoietic progenitor cells useful as a therapy for various hematopoietic diseases and useful for improvement in the efficiency of gene transfer into hematopoietic stem cells for gene therapy is provided. A method of producing hematopoietic stem cells and/or hematopoietic progenitor cells, which comprises expanding hematopoietic stem cells by culturing hematopoietic stem cells ex vivo in the presence of a compound represented by the formula following (I), a tautomer or pharmaceutically acceptable salt of the compound or a solvate thereof (wherein R1 to R8 are as defined in the description).
Type:
Grant
Filed:
December 1, 2011
Date of Patent:
December 15, 2015
Assignees:
NISSAN CHEMICAL INDUSTRIES, LTD., REPROCELL INCORPORATED
Abstract: The present invention relates to compositions and methods for creation of vector nucleic acid sequences (e.g., retroviral nucleic acid sequences) that comprise two or more exogenous nucleic acid sequences that encode highly homologous (e.g., identical) polypeptide sequences, yet wherein at least one of the exogenous nucleic acid sequences has been mutated using degenerate codons for purpose of reducing homology between the two or more exogenous nucleic acid sequences while maintaining the encoded polypeptide sequence. Preferred nucleic acid sequences include those encoding multi-chimeric immune receptor (CIR) genes. Specific nucleic acid sequences of such CIR genes are also disclosed.
Type:
Grant
Filed:
January 22, 2010
Date of Patent:
December 8, 2015
Assignee:
ROGER WILLIAMS HOSPITAL
Inventors:
Wen Yang, Richard P. Junghans, Anthony J. Bais
Abstract: Use of low dose streptozocin in the preparation of an animal model for screening drugs for treatment of antoimmune type 1 diabetes is disclosed, in which streptozocin is administrated intravenously at a dose of 15-30 mg/kg per time for 5 days and administrated again on the 7th day and 14th day after last time of offering drug. A method for preparing rhesus monkey model of autoimmune type 1 diabetes and autoimmune type 1 diabetes animal model obtained are also disclosed.
Type:
Grant
Filed:
March 26, 2010
Date of Patent:
November 17, 2015
Assignee:
West China Hospital, Sichuan University
Inventors:
Yanrong Lu, Jingqiu Cheng, Shaoping Deng, Younan Chen, Bole Tian, Gang Mai, Yan Ren, Li Wang, Hongxia Li, Lingling Wei, Xi Jin, Chaofeng Qiao, Wensheng Zhang, Sirong He, Li Zeng
Abstract: The present invention provides compositions useful for cardiac therapy comprising a cyclin-associated agent. The present invention also provides kits for use in delivering a cyclin-associated agent to cardiac cells in a subject, comprising the composition of the present invention and a catheter. The present invention additionally provides a methods for enhancing cardiac function; promoting regeneration of cardiac tissue; inducing endogenous myocardial regeneration; and preventing or treating heart failure in a subject in need thereof by augmenting cyclin in cells.
Type:
Grant
Filed:
December 18, 2009
Date of Patent:
September 15, 2015
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: The invention relates to a multiwell system, characterized that said multiwell system having at least 3 wells, wherein said wells have a volume between 0.125 and 4.0 mm3.
Type:
Grant
Filed:
July 6, 2011
Date of Patent:
September 15, 2015
Assignee:
UNIVERSITEIT TWENTE
Inventors:
Gustavo Andres Higuera, Lorenzo Moroni, Clemens Antoni van Blitterswijk
Abstract: Methods for treating inflammation are disclosed, such as for treating ocular inflammation. In some embodiments, the ocular inflammation is inflammation of an ocular surface, such as keratitis. The methods include administering to a subject with inflammation a therapeutically effective amount of SLURP1, or a nucleic acid encoding SLURP1, thereby treating the inflammation.
Type:
Grant
Filed:
November 4, 2013
Date of Patent:
September 15, 2015
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education
Inventors:
Shivalingappa Kottur Swamynathan, Sudha Swamynathan, Kristine-Ann Gallegos Buela, Robert Lee Hendricks
Abstract: The present invention comprises methods and systems for manipulation of media and particles, whether inert materials or biomaterials, such as cells in suspension cell culture. The methods and systems comprise use of an apparatus comprising a rotating chamber wherein the actions of the combined forces fluid flow force and centrifugal force form a fluidized bed within the rotating chamber.
Type:
Grant
Filed:
July 16, 2009
Date of Patent:
July 28, 2015
Assignee:
KBI Biopharma, Inc.
Inventors:
Sunil Mehta, Tod Herman, Harold Ross, Khurshid Iqbal, Joe McMahon
Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.
Type:
Grant
Filed:
February 13, 2009
Date of Patent:
June 30, 2015
Assignee:
Cambridge Enterprise Limited
Inventors:
David Cox, Dennis Ballinger, Bruce Ponder, Doug Easton
Abstract: Correlations between polymorphisms and breast cancer are provided. Methods of diagnosing, prognosing, and treating breast cancer are provided. Systems and kits for diagnosis, prognosis and treatment of breast cancer are provided. Methods of identifying breast cancer modulators are also described.
Type:
Grant
Filed:
September 24, 2010
Date of Patent:
June 9, 2015
Assignee:
Cambridge Enterprise Limited
Inventors:
David Cox, Dennis Ballinger, Bruce Ponder, Doug Easton
Abstract: Described are (a) parvovirus variants capable of propagating and spreading through human tumor cells which is obtainable by serially passaging a rodent parvovirus as starting strain in semi-permissive human tumor cells, and (b) parvovirus variants capable of propagating and spreading through human tumor cells characterized by particular amino acid deletions and/or substitutions, e.g. a deletion of several amino acids in the C-terminus of NS1/middle exon of NS2. A pharmaceutical composition containing such parvoviruses as well as their use for the treatment of cancer, preferably a glioblastoma, is also described.
Type:
Grant
Filed:
May 9, 2011
Date of Patent:
May 12, 2015
Assignee:
Deutsches Krebsforschungzentrum
Inventors:
Jürg Nüesch, Nadja Thomas, Claudia Plotzky, Jean Rommelaere
Abstract: The present invention relates generally to transgene constructs, transgenic non-human animals comprising transgene constructs, methods of making and methods of using the transgenic non-human animals comprising transgene constructs. An embodiment of the invention relates to methods of assaying the activation of GPCR ligands non-invasively in whole animals, tissue slices, or in native cells using a transgenic model containing a bioluminescent transgene reporter system that is responsive to pathway modulation following ligand binding of GPCR receptors.
Type:
Grant
Filed:
December 17, 2010
Date of Patent:
March 17, 2015
Assignee:
Sanofi
Inventors:
Holly Dressler, Kyriakos D. Economides, Zhen Pang, Harry Gregory Polites
Abstract: Use of intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein and/or a nucleic acid molecule encoding for the intracytoplasmatic domain of Anaplastic Lymphoma Kinase (ALK) protein, of any species, for the preparation of a medicament, preferably a vaccine, for the treatment and/or prevention of a tumor in a subject, preferably a lymphoma.
Type:
Grant
Filed:
September 25, 2008
Date of Patent:
March 17, 2015
Inventors:
Roberto Chiarle, Giorgio Inghirami, Guido Forni
Abstract: Genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein are provided. Also provided are genetically modified mice comprising a nucleic acid sequence encoding a human M-CSF protein that have been engrafted with human cells such as human hematopoietic cells, and methods for making such engrafted mice. These mice find use in a number of applications, such as in modeling human immune disease and pathogen infection; in in vivo screens for agents that modulate hematopoietic cell development and/or activity, e.g. in a healthy or a diseased state; in in vivo screens for agents that are toxic to hematopoietic cells; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on hematopoietic cells; in in vivo screens of human hematopoietic cells from an individual to predict the responsiveness of an individual to a disease therapy, etc.
Type:
Grant
Filed:
February 14, 2012
Date of Patent:
September 30, 2014
Assignees:
Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
Inventors:
Andrew J. Murphy, Sean Stevens, Chozhavendan Rathinam, Elizabeth Eynon, Markus Manz, Richard Flavell, George D. Yancopoulos
Abstract: A transgenic insect cell line for production of elevated levels of recombinant glycoproteins comprising mammalian-like N-glycans is provided. Also disclosed are nucleic acid sequences encoding ?-N-acetylglucosaminidases.